SCHEMBL266991

SCHEMBL266991

CC(C)(C)OC(=O)NC[C@@H](C(=O)N(CCc1ccc(C(F)(F)F)nc1)c1ccc2c(c1)OCC2)c1ccccc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
EP300 Q09472 1/20 0.32
OGA O60502 2/20 0.32
SCN5A Q14524 1/20 0.32
SCN9A Q15858 1/20 0.32
USP9X Q93008 1/20 0.32
TRPV1 Q8NER1 2/20 0.32
OPRM1 P35372 1/20 0.32
KCNK3 O14649 2/20 0.31
P2RX7 Q99572 4/20 0.31
PLAAT3 P53816 1/20 0.31
PLAAT5 Q96KN8 1/20 0.31
PLAAT2 Q9NWW9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266989 1.00 KDM4E (0.33) KDM4EALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL266990 1.00 KDM4E (0.33) KDM4EALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL13574545 0.94 NR3C1 (0.34) OGATRPV1KCNK3P2RX7
Hydrochloric Acid SCHEMBL265960 0.85 USP9X (0.34) EP300OGASCN5ASCN9AUSP9X
Hydrochloric Acid SCHEMBL265961 0.85 USP9X (0.34) EP300OGASCN5ASCN9AUSP9X
Hydrochloric Acid SCHEMBL265962 0.85 USP9X (0.34) EP300OGASCN5ASCN9AUSP9X
SCHEMBL271721 0.80 NR3C1 (0.36) OGATRPV1OPRM1KCNK3
SCHEMBL271525 0.79 OGA (0.33) OGATRPV1KCNK3P2RX7
SCHEMBL265895 0.76 OGA (0.34) OGASCN5ASCN9AUSP9XTRPV1
SCHEMBL265893 0.76 OGA (0.34) OGASCN5ASCN9AUSP9XTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133909-B2 Heteroaromatic monoamides as orexinin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2297102-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-03-23 EP disclosed
WO-2009153180-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 KDM4E 3175/4885ALDH1A1 1706/4885CYP1A2 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.